Being told that testicular cancer is Stage I, Stage 1, or “confined to the testicle” can bring relief, but patients often have an important next question: Do I need chemotherapy, or can I be monitored after surgery?
After radical inguinal orchidectomy (also called radical inguinal orchiectomy), the next step is to review the histopathology report, post-operative tumour-marker results and staging scans. If these indicate that the cancer is limited to the testicle and there is no evidence of spread, some patients can be managed with active surveillance. Others may be offered additional treatment depending on the tumour type, pathological risk factors and clinical findings.
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with a surgical interest in testicular cancer and complex retroperitoneal disease. This page explains the options that may be discussed after surgery. The right choice must be made individually with the treating team.
Stage I testicular cancer generally means that the tumour has been removed from the testicle and staging assessment has not identified spread to distant lymph nodes or organs. The exact classification depends on the pathology, tumour markers and imaging.
Patients may see these phrases in reports or hear them during consultation:
“No spread seen on the CT scan” is encouraging, but the complete assessment also includes histopathology and tumour-marker trends. Very small deposits may not be visible on imaging, which is one reason follow-up is important.
The post-operative plan is based on several pieces of information rather than one report alone.
The pathology report confirms the tumour type and describes features that may influence the risk of recurrence. The tumour may be a seminoma, a non-seminomatous germ cell tumour (NSGCT) or a mixed germ cell tumour.
For non-seminomatous tumours, one important feature is lymphovascular invasion (LVI)—whether tumour cells are seen in lymphatic or blood vessels within the specimen. Other pathological features and the exact tumour category also matter.
AFP (alpha-fetoprotein), beta-hCG (beta-human chorionic gonadotropin) and LDH (lactate dehydrogenase) are assessed before and after surgery when indicated.
The treating team considers whether markers are falling as expected, have returned to the normal range, remain elevated or are rising. The timing of each blood test matters because markers have different biological half-lives.
Persistently elevated or rising tumour markers after orchidectomy need prompt specialist assessment. They may indicate disease that is not visible on initial imaging and can change the stage and treatment plan. This situation is not managed in the same way as uncomplicated Stage I disease with normalising markers.
CT of the abdomen and pelvis, and chest imaging when indicated, help assess for retroperitoneal lymph nodes or disease elsewhere. Reports may use phrases such as “no significant retroperitoneal lymphadenopathy,” “no CT evidence of metastatic disease,” or “no enlarged para-aortic or interaortocaval lymph nodes.”
Imaging findings must be interpreted with the pathology and markers. If a lymph node is enlarged or indeterminate, the team may recommend further assessment or repeat imaging rather than assuming either spread or absence of disease.
For many patients with Stage I testicular cancer, the options include:
The best option is not the same for everyone. The discussion should include the risk of recurrence, the likelihood that additional treatment can be avoided, side effects, fertility considerations, follow-up requirements and the patient’s ability to attend surveillance reliably.
Stage I seminoma is often managed with active surveillance after orchidectomy when staging is appropriate and the patient can follow the recommended schedule.
Seminoma is a type of germ cell tumour. Many patients are cured by surgery alone, and surveillance allows additional treatment to be reserved for the patients who develop evidence of recurrence. Surveillance does not mean that the cancer is being ignored; it is a structured plan designed to detect recurrence early.
Depending on the protocol, follow-up may include:
The exact schedule varies by guideline, risk assessment and local practice. Patients should follow the written plan from their treating team rather than use a generic online schedule.
Selected patients may discuss adjuvant carboplatin chemotherapy after orchidectomy. It can reduce the risk of relapse, but it also exposes patients to treatment that many would never have needed if managed with surveillance. The decision should consider individual risk, medical factors, preferences and ability to attend follow-up.
Radiotherapy has a limited role in modern management and is considered only in selected circumstances because of potential late effects. It is not routinely required for every patient with Stage I seminoma.
Stage I non-seminomatous germ cell tumour can include embryonal carcinoma, yolk sac tumour, choriocarcinoma, teratoma or a mixed germ cell tumour. Management differs from seminoma, so the exact histopathology report is important.
For many patients, surveillance is an option after orchidectomy. Some patients may be offered adjuvant chemotherapy, while RPLND may be considered in selected cases depending on the tumour type, pathological findings and clinical context.
Lymphovascular invasion (LVI) means that tumour cells are identified within lymphatic or blood vessels in the specimen. In Stage I NSGCT, LVI is an important risk factor for recurrence and can influence the discussion about surveillance versus adjuvant treatment.
Other pathological findings may also be relevant. LVI does not automatically mean that visible metastases are present, and the treatment choice should be based on the full pathology and staging assessment.
The pT category and features such as LVI contribute to the pathological classification. In general, Stage IA corresponds to a lower local pathological category without certain higher-risk features, while Stage IB includes a higher pT category. The precise classification should be taken from the pathology and staging assessment, not guessed from one phrase.
Patients may see terms such as pT1, pT2, pT3, pT4, LVI-positive, LVI-negative, embryonal carcinoma component or mixed germ cell tumour. The significance of each term depends on the complete report.
No. Surveillance is an accepted option for many patients, and adjuvant chemotherapy may be discussed for selected patients to lower recurrence risk. The potential benefit must be balanced against treatment-related side effects and the fact that some patients would remain cured by orchidectomy alone.
The decision should consider pathology, tumour-marker results, imaging, patient preference and the ability to complete follow-up.
Patients may see phrases such as:
These findings require specialist reassessment. Persistently elevated or rising markers can indicate disease beyond the removed testicle even if initial scans do not show enlarged lymph nodes. The team may repeat tests at appropriate intervals, review marker half-lives, reassess imaging and determine whether the disease should be managed as a higher stage.
A single mildly abnormal result does not always establish progression; the trend, timing, tumour type and possible non-cancer causes need careful interpretation. Do not delay review if your treating team has asked for repeat markers or further staging.
A CT scan reported as “no evidence of metastatic disease” or “no significant retroperitoneal lymphadenopathy” is an important part of staging, but it does not eliminate the need for follow-up.
Microscopic disease may not be visible on a scan. Surveillance is designed to identify recurrence through a combination of clinical assessment, tumour markers and scheduled imaging. If a report describes an indeterminate or borderline-sized lymph node, the treating team may recommend review of the images and interval imaging according to the clinical situation.
Active surveillance is a planned programme of follow-up after orchidectomy without immediate additional treatment. It commonly includes medical visits, examination, tumour-marker testing and scheduled imaging.
It is different from simply waiting for symptoms. Many recurrences can be detected by the planned tests before symptoms develop, and patients who relapse can receive treatment according to the site and extent of disease.
Surveillance is most appropriate when the patient understands the plan and can attend the required visits.
Adjuvant chemotherapy means chemotherapy given after the primary tumour has been removed, with the aim of reducing the risk of recurrence.
For Stage I disease, it may be discussed in selected situations. The regimen and number of cycles depend on the tumour type and the clinical plan. Chemotherapy can cause side effects, and the treating oncologist should explain both short- and long-term considerations before treatment.
Adjuvant chemotherapy is not the same as chemotherapy for visible metastatic disease. The reason for treatment, expected benefit and follow-up plan should be explained clearly.
Retroperitoneal lymph node dissection (RPLND) is an operation to remove selected lymph nodes in the back of the abdomen. It is not routine for every patient with Stage I testicular cancer.
In selected patients with NSGCT, RPLND may be discussed as part of management depending on pathological features, tumour composition, marker results and specialist assessment. It may also be used in other settings, including selected residual masses after chemotherapy, which are discussed on a separate page.
RPLND is a different operation from orchidectomy. It involves deeper abdominal anatomy and has its own potential risks, including effects on ejaculation. The choice should be made with a team experienced in testicular cancer.
The discussion usually considers:
A decision should not be based on fear alone or on a single pathology phrase. Patients should have an opportunity to ask questions and understand why a particular option is being recommended.
Testicular cancer often affects men who are planning their families. Fertility may be influenced by the cancer itself, the function of the remaining testicle and additional treatments.
If chemotherapy or RPLND is being considered, discuss fertility preservation and sperm banking before treatment when feasible. RPLND can affect ejaculation in some cases; nerve-sparing approaches may help selected patients but cannot guarantee preservation. The specific risks depend on the operation and disease.
Long-term follow-up should also address physical recovery, sexual health, hormone-related symptoms, emotional wellbeing and return to normal activities.
Contact your treating team if you notice new or persistent symptoms, or if a scheduled test is abnormal. Depending on the clinical context, symptoms may include persistent back or abdominal pain, a new abdominal lump, unexplained cough or breathlessness, new swelling, or other symptoms that concern you.
These symptoms do not automatically mean recurrence. They need assessment in context. Do not wait until the next scheduled appointment if your team has advised you to report a particular symptom or abnormal result promptly.
Stage I testicular cancer is highly curable. The recommended plan depends on the tumour type, pathology, markers and staging. Your treating team can explain the outlook for your specific diagnosis.
Yes. Microscopic disease may not be visible on CT. Scheduled surveillance uses clinical review, blood tests and imaging to detect recurrence early.
No. Many patients can be managed with surveillance. Adjuvant chemotherapy is considered in selected cases after discussing recurrence risk, benefits, side effects and alternatives.
For appropriately selected patients who can follow the protocol, surveillance is an established management option. It requires reliable attendance at appointments, blood tests and imaging.
They are different germ cell tumour categories and their management pathways are not identical. Histopathology, LVI and other features help guide the options after orchidectomy.
It means tumour cells are seen within lymphatic or blood vessels in the specimen. In Stage I non-seminomatous germ cell tumour, it is an important factor in assessing recurrence risk.
It can refer to a situation where tumour markers remain elevated after orchidectomy despite no clear metastatic disease on imaging. It needs specialist reassessment because management may differ from Stage I disease with markers that normalise.
Yes, recurrence is possible. The purpose of surveillance is to identify it early so that appropriate treatment can be given. Follow-up schedules should be followed carefully.
Bring the histopathology report, pre- and post-operative AFP, beta-hCG and LDH results with dates, CT reports and images, the operative note and any previous treatment records.
| Test | What it shows | How it is used |
|---|---|---|
| AFP, beta-hCG, LDH | Whether markers normalise after surgery | Persistent elevation suggests disease beyond the testis |
| CT chest, abdomen, pelvis | Retroperitoneal nodes and distant disease | Confirms Stage I or upstages the tumour |
| Histopathology | Tumour type and invasion features | Defines risk factors for relapse |
Surveillance is an accepted option for many Stage I patients, because most are cured by orchidectomy alone and a relapse found early can be treated effectively. It needs regular tumour markers and CT imaging on schedule.
Adjuvant chemotherapy (BEP in non-seminoma, or carboplatin in seminoma) may be offered when risk factors are present, such as lymphovascular invasion in non-seminoma or tumour above 4 cm with rete testis invasion in seminoma.
AFP and hCG should fall according to their half-lives, about 5 to 7 days for AFP and 1 to 3 days for hCG. A plateau or rise suggests residual disease and needs review.
Selected videos and anonymised case summaries from Dr Swati Shah’s testicular cancer practice, shared for patient education. Every patient’s plan is individual, and a past case does not predict an individual result.
When a testicular tumour is suspected, the surgical approach is extremely important. A scrotal incision should generally be avoided because it can disrupt the normal lymphatic drainage pathways of the testis and potentially increase the risk of local tumour contamination and altered patterns of spread.
The standard oncological procedure for a suspected testicular malignancy is high inguinal orchidectomy. Through an inguinal approach, the testis is delivered and removed along with the spermatic cord and its vascular and lymphatic pedicle, providing appropriate oncological control and allowing accurate histopathological diagnosis.
This is an important surgical principle: the first incision matters. An incorrect approach can complicate subsequent management, while the appropriate initial procedure can help ensure proper staging and treatment.
जब टेस्टिकुलर ट्यूमर (Testicular Tumour) का संदेह हो, तो सर्जरी का सही तरीका बहुत महत्वपूर्ण होता है। आमतौर पर अंडकोष (Scrotum) पर चीरा लगाने से बचना चाहिए, क्योंकि इससे अंडकोष की सामान्य लिम्फेटिक ड्रेनेज (Lymphatic drainage) प्रभावित हो सकती है और स्थानीय रूप से ट्यूमर कोशिकाओं के फैलने तथा बीमारी के फैलाव के तरीके में बदलाव का जोखिम बढ़ सकता है।
संदिग्ध टेस्टिकुलर कैंसर में मानक ऑन्कोलॉजिकल सर्जरी हाई इंग्वाइनल ऑर्किडेक्टॉमी (High Inguinal Orchidectomy) है। इसमें जांघ के ऊपरी हिस्से के पास इंग्वाइनल (Inguinal) रास्ते से अंडकोष को बाहर निकालकर, उसे स्पर्मेटिक कॉर्ड (Spermatic cord) तथा उसकी रक्त वाहिकाओं और लिम्फेटिक पेडिकल (Lymphatic pedicle) सहित हटाया जाता है। इससे उचित कैंसर सर्जरी सुनिश्चित होती है और सही हिस्टोपैथोलॉजिकल डायग्नोसिस (Histopathological diagnosis) में मदद मिलती है।
यह एक महत्वपूर्ण सर्जिकल सिद्धांत है: पहला चीरा बहुत मायने रखता है। गलत तरीके से किया गया पहला ऑपरेशन आगे के उपचार को जटिल बना सकता है, जबकि सही शुरुआती सर्जिकल प्रक्रिया बीमारी की उचित स्टेजिंग और आगे के उपचार में मदद करती है।
Advanced testicular cancer can still be curable, even when large residual lymph node masses remain after chemotherapy.
In this case, a 30-year-old man with a mixed germ cell tumor of the testis received systemic chemotherapy and subsequently underwent evaluation for a residual retroperitoneal lymph node mass. PET-CT showed significant residual masses measuring approximately 6 × 5 cm and 5 × 5 cm, located close to major blood vessels, including the aorta, inferior vena cava (IVC), and renal vessels.
Because of the size and location of the residual disease, surgery was technically challenging. The patient underwent exploratory laparotomy with retroperitoneal lymph node dissection (RPLND). Despite the close relationship of the tumor to the major vessels, a complete surgical resection was achieved safely, with removal of all visible residual tumor tissue.
This video presents a compelling testimonial from a testicular cancer survivor who received life-saving treatment from Dr. Swati Shah, an expert Uro and Gynecological Oncologist. In the brief clip, the patient recounts their challenging medical journey, focusing on the critical decision-making process regarding their surgical treatment plan. Initially confronted with the difficult prospect of traditional open surgery—which typically involves a longer, more painful healing process—the patient instead opted for a state-of-the-art robotic surgery performed by Dr. Shah. The survivor shares how this advanced, minimally invasive approach made a massive difference in their overall recovery.
In the video, He speaks in Gujarati, sharing his personal experience. He explains that he initially visited the clinic because he was experiencing significant pain. After a thorough medical evaluation, he was diagnosed with cancer and advised to undergo surgical intervention. Guided by the medical expertise of Dr. Swati Shah, He confidently went ahead with the recommended operation. The surgery was a success, and he reports receiving a highly positive response to the procedure. Following the operation, his comprehensive treatment plan also included a round of chemotherapy to reduce the risk of relapse.
The patient explains that he was initially diagnosed with testicular cancer five years ago. Unfortunately, eight months prior to the video, he faced a recurrence involving a retroperitoneal lymph node. After finding Dr. Swati Shah online, he underwent a complex robotic Retroperitoneal Lymph Node Dissection (RPLND) surgery performed by her. Speaking just two months post-operation, the patient highlights his remarkably smooth and rapid recovery, noting that his follow-up medical reports have all been positive. He expresses deep gratitude and recommends Dr. Shah.
A 31-year-old man had right scrotal swelling for six months. Ultrasound showed a 6.7 × 4.9 cm hypoechoic mass and AFP was 479.3, so high inguinal orchidectomy was advised, with histopathology and staging to follow.
A 36-year-old man had a hard, non-tender right testicular swelling for one year. Imaging showed a complex 7.3 × 6.3 cm lesion with raised LDH and AFP. Because of its size and possible involvement of the scrotal wall, a right high inguinal orchidectomy was performed.
Details are anonymised and shown for education only.
My name is Bharat. I have testis cancer. I have a lot of money and I am going to have an operation but I am very happy with the support of Dr. Swati Shah. I am very happy with the support of Dr. Swati Shah. I am very happy with the support of Dr. Swati Shah. Thank you very much.
From the first meeting, Dr. Swati Shah explained every detail of the diagnosis and surgical procedure with great clarity. During the surgery, her precision and care were remarkable, and post-surgery recovery was smooth under her guidance.
Jayshrikrishna… Mam no response bavj Saras che, khubj Saras rite Amne samjhayu che detail ma.. madam no nature Khubj Santoshkarak che.. Thank you mam..
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with a surgical interest in testicular cancer and complex retroperitoneal disease.
If you have undergone orchidectomy and are unsure whether surveillance, chemotherapy or further surgery is appropriate, a specialist review of the histopathology, tumour-marker trend and staging images can help clarify the next steps.
Consultation: Shah’s Cancer & Robotic Surgery Centre, Gota, Ahmedabad.
Hospital: Apollo Hospital International, Ahmedabad, as appropriate.
Contact: +91 63590 11009
This page is for general education and does not replace an individual medical consultation. Follow-up schedules and treatment choices must be individualised by the treating team.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
